None listed
Conditions
Brief summary
One in seven women will experience depression or anxiety after the birth of their baby; however 60% of cases will go undetected. The identification of postnatal depression (PND) or anxiety is not part of the routine care provided by health care systems, meaning that only 10% of women experiencing these difficulties will receive treatment. This is mainly due to not screening for, and identifying, postnatal depression or anxiety. Although methods to identify PND exist, they are inconsistently carried out, and are prone to error as primary care professionals lack time as well as a clear system when making decisions on how to manage depression. We have co-developed a tablet-based application (e-screening tool) to screen for postnatal depression and to conduct a broad assessment of a woman’s well-being. This tool will help health professionals to identify postnatal depression and/or anxiety easily, accurately and consistently and provide best-practice guidance tailored to women’s responses. To determine whether our e-screening tool will be useful for health professionals in identifying PND, we will compare it to the existing method of screening and identification that is currently used by health professionals. The success of the new system will be measured by its capacity to deliver real improvements to the healthcare system. The new e-screening tool aims to be quicker, more accurate, involve less staff time and resources, be used more frequently, and lead to improvements in treatment and recovery rates for depressed women. Ultimately, this trial could lead to a cost-effective and sustainable new system.
Interventions
PIRIMID. During study period 1, Maternal and child health nurses (MCHNs) in this condition will use an e-screening (originally "iCOPE") and clinician decision support system (PIRIMID) as part of each woman's emotional health assessment during her 4-week Key Ages and Stages (KAS) visit at the maternal and child health centre. Using a tablet-based electronic screening system for carrying out perinatal depression screening, PIRIMID provides clinical decision support to health professionals. It includes the Whooley questions, Edinburgh Postnatal Depression Scale (EPDS) and psychosocial questions following the beyondblue Clinical Practice Guidelines for Depression and Related Disorders in the Perinatal Period. The woman answers the questions on the tablet herself (approximately 5 minutes). PIRIMID automatically scores the EPDS and the other psychosocal information is collated. The MCHN is then provided with reports offering guidance, support and prompts for best-practice management tailored to each individual woman's data. Adherence to the intervention will be monitored using a Logbook specifically developed for this study on which information is recorded about the number of potential participants, number who agree to participate in the study, and number screened using the PIRIMID system. This data will be compared with completed consent forms, data from the PIRIMID system and service level data to monitor adherence. In period 2, twelve months into the trial, MCHNs in this condition will cross over to provide standard care (described below).
Sponsors
Study design
Eligibility
Inclusion criteria
Ability to understand spoken and written language Baby aged 4-6 weeks
Exclusion criteria
nil